Literature DB >> 22578894

Effect of hydroxyethyl starch on bleeding after cardiopulmonary bypass: a meta-analysis of randomized trials.

Roberta J Navickis1, Gary R Haynes, Mahlon M Wilkes.   

Abstract

OBJECTIVE: The effects of hydroxyethyl starch on bleeding after cardiopulmonary bypass were determined.
METHODS: A meta-analysis was performed of postoperative blood loss in randomized clinical trials of hydroxyethyl starch versus albumin for fluid management in adult cardiopulmonary bypass surgery. Impacts of hydroxyethyl starch molecular weight and molar substitution were assessed. Randomized trials directly comparing different hydroxyethyl starch solutions were also included.
RESULTS: Eighteen trials with 970 total patients were included. Compared with albumin, hydroxyethyl starch increased postoperative blood loss by 33.3% of a pooled SD (95% confidence interval, 18.2%-48.3%; P < .001). Risk of reoperation for bleeding was more than doubled by hydroxyethyl starch (relative risk, 2.24; 95% confidence interval, 1.14-4.40; P = .020). Hydroxyethyl starch increased transfusion of red blood cells by 28.4% of a pooled SD (95% confidence interval, 12.2%-44.6%; P < .001), of fresh-frozen plasma by 30.6% (95% confidence interval, 8.0%-53.1%; P = .008), and of platelets by 29.8% (95% confidence interval, 3.4%-56.2%; P = .027). None of these effects differed significantly between hydroxyethyl starch 450/0.7 and 200/0.5. Insufficient data were available for hydroxyethyl starch 130/0.4 versus albumin; however, no significant differences were detected in head-to-head comparisons of hydroxyethyl starch 130/0.4 with 200/0.5. Albumin improved hemodynamics. There were no differences in fluid balance, ventilator time, intensive care unit stay, or mortality.
CONCLUSIONS: Hydroxyethyl starch increased blood loss, reoperation for bleeding, and blood product transfusion after cardiopulmonary bypass. There was no evidence that these risks could be mitigated by lower molecular weight and substitution.
Copyright © 2012 The American Association for Thoracic Surgery. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22578894     DOI: 10.1016/j.jtcvs.2012.04.009

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  28 in total

1.  Does removing Mannitol and Voluven from the priming fluid of the cardiopulmonary bypass circuit have clinical effects?

Authors:  Matthew D Haydock; Cornelis Kruger; Timothy Willcox; David A Haydock
Journal:  J Extra Corpor Technol       Date:  2014-03

2.  Cross-Sectional Guidelines for Therapy with Blood Components and Plasma Derivatives: Chapter 5 Human Albumin - Revised.

Authors: 
Journal:  Transfus Med Hemother       Date:  2016-05-03       Impact factor: 3.747

Review 3.  [Limited applications for hydroxyethyl starch : background and alternative concepts].

Authors:  M Rehm
Journal:  Anaesthesist       Date:  2013-08       Impact factor: 1.041

4.  The effect of fibrinogen concentrate and factor XIII on thromboelastometry in 33% diluted blood with albumin, gelatine, hydroxyethyl starch or saline in vitro.

Authors:  Christoph Johannes Schlimp; Janne Cadamuro; Cristina Solomon; Heinz Redl; Herbert Schöchl
Journal:  Blood Transfus       Date:  2012-12-13       Impact factor: 3.443

5.  Bleeding and risk of death with hydroxyethyl starch in severe sepsis: post hoc analyses of a randomized clinical trial.

Authors:  Nicolai Haase; Jørn Wetterslev; Per Winkel; Anders Perner
Journal:  Intensive Care Med       Date:  2013-10-01       Impact factor: 17.440

Review 6.  Fluid management in living donor hepatectomy: Recent issues and perspectives.

Authors:  Seong-Soo Choi; Sung-Hoon Kim; Young-Kug Kim
Journal:  World J Gastroenterol       Date:  2015-12-07       Impact factor: 5.742

7.  Hydroxyethyl starch: putting patient safety first.

Authors:  Julian Bion; Rinaldo Bellomo; John Myburgh; Anders Perner; Konrad Reinhart; Simon Finfer
Journal:  Intensive Care Med       Date:  2013-12-19       Impact factor: 17.440

8.  STS/SCA/AmSECT/SABM Update to the Clinical Practice Guidelines on Patient Blood Management.

Authors:  Pierre Tibi; R Scott McClure; Jiapeng Huang; Robert A Baker; David Fitzgerald; C David Mazer; Marc Stone; Danny Chu; Alfred H Stammers; Tim Dickinson; Linda Shore-Lesserson; Victor Ferraris; Scott Firestone; Kalie Kissoon; Susan Moffatt-Bruce
Journal:  J Extra Corpor Technol       Date:  2021-06

9.  Effect of 6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride (Voluven®) on complications after subarachnoid hemorrhage: a retrospective analysis.

Authors:  Shariq A Khan; Owoicho Adogwa; Tong J Gan; Ulysses T Null; Terence Verla; Sankalp Gokhale; William D White; Gavin W Britz; Ali R Zomorodi; Michael L James; David L McDonagh
Journal:  Springerplus       Date:  2013-07-15

10.  Hydroxyethyl starch in severe sepsis: end of starch era?

Authors:  Carlos A Estrada; Raghavan Murugan
Journal:  Crit Care       Date:  2013-03-13       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.